SCHEMBL23458355

SCHEMBL23458355

CCCCc1cc(N(CC)CC)c2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BCHE P06276 2/20 0.40
ABCB11 O95342 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
SCN1A P35498 1/20 0.39
SCN2A Q99250 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SCN3A Q9NY46 1/20 0.39
PSMB5 P28074 1/20 0.39
MAPT P10636 1/20 0.38
CRHR1 P34998 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
KCNH2 Q12809 1/20 0.36
DHODH Q02127 1/20 0.36
CTSV O60911 1/20 0.35
CTSL P07711 1/20 0.35
KEAP1 Q14145 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29862546 1.00 LMNA (0.40) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL28641542 0.81 MAPT (0.48) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL27279895 0.77 TLR8 (0.45) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL5252565 0.76 PSMB5 (0.40) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL8728861 0.76 LMNA (0.42) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL8728863 0.76 LMNA (0.42) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL28783566 0.76 PLAU (0.41) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL7308613 0.76 MAPT (0.44) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL3272457 0.75 TDP1 (0.44) LMNAALDH1A1SMN1; SMN2BCHEABCB11
SCHEMBL25991550 0.74 CA1 (0.47) LMNAALDH1A1SMN1; SMN2MAPTDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12510529-B2 Method for determining authenticity and adulteration of marked petroleum hydrocarbons SICPA HOLDING SA (CH) 2025-12-30 US disclosed
EP-4069806-B1 METHOD OF MARKING A PETROLEUM HYDROCARBON SICPA HOLDING SA (CH) 2025-04-16 EP disclosed
US-20240327736-A1 METHOD OF MARKING A PETROLEUM HYDROCARBON SICPA HOLDING SA (CH) 2024-10-03 US disclosed
EP-4069807-B1 METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS SICPA HOLDING SA (CH) 2023-10-04 EP disclosed
US-20230103579-A1 METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS SICPA HOLDING SA (CH) 2023-04-06 US disclosed
WO-2021110525-A1 METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS SICPA HOLDING SA (CH) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12510529-B2 Method for determining authenticity and adulteration of marked petroleum hydrocarbons CYP4A11, CYP11B1, CYP11A1 LMNA 10/4885ALDH1A1 444/4885SMN1; SMN2 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.